A
$ Value
$0
Shares
437,500
Price
$0
Filed
Oct 2
Insider
Name
Hasnain Faheem
Title
President & CEO
CIK
0001352620
Roles
Director
Officer
Transaction Details
Transaction Date
2025-10-01
Code
A
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
557,793
Footnotes
Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer.